David L. Veenstra, PharmD, PhD, Professor and Associate Director, Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, Department of Pharmacy, University of Washington
Rapidly decreasing genetic testing costs have brought population-wide genomic screening within the realm of possibilities. But high-risk monogenic conditions are rare and prevention strategies will lead to additional healthcare costs. Dr. Veenstra will present the results of decision-analytic simulation models assessing the cost effectiveness of genomic screening for risk of breast and ovarian cancer, colorectal cancer, and cardiovascular disease.
Seminar on Ethical, Legal and Social Implications of Genetics
Center for Research on Ethical/Legal/Social Implications of Psychiatric, Neurologic & Behavioral Genetics, Department of Psychiatry and the Precision Medicine Resource, Irving Institute for Clinical and Translational Research, Columbia University Irving Medical Center
To register for this online presentation and receive the Zoom link, please send an email with your name and affiliation to Alfa.Garcia@nyspi.columbia.edu